glp-1 medications lean muscle retention weight loss From Fat Burn to Build: The Future of Obesity beyond GLP- 1 Nutritional priorities to support GLP-1

The trial is currently in an open-label extension phase, with expected completion in January 2027, to investigate liraglutides long-term efficacy and safety effects

Agent-specific information is summarized below

In addition to regulating blood sugar and lowering body weight in non-diabetic obese patients, tirzepatide can also lower liver fat and improve kidney outcomes (Rosenstock et al., 2025)

Bookmark our Insights to Activate series exploring a range of timely topics, featuring impactful insights today that you can activate tomorrow.

This seems to be a rare and unusual complication of GLP-1 medication use, as millions of people have been using these types of medications for many years, Ali commented

There have been many promising studies showing how GLP-1 expands far beyond just weight loss in longevity